117 related articles for article (PubMed ID: 23177726)
1. Synthesis and biological evaluation of a folate-targeted rhaponticin conjugate.
Liang X; Sun Y; Zeng W; Liu L; Ma X; Zhao Y; Fan J
Bioorg Med Chem; 2013 Jan; 21(1):178-85. PubMed ID: 23177726
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of EC72: a new folate-targeted chemotherapeutic.
Leamon CP; Reddy JA; Vlahov IR; Vetzel M; Parker N; Nicoson JS; Xu LC; Westrick E
Bioconjug Chem; 2005; 16(4):803-11. PubMed ID: 16029021
[TBL] [Abstract][Full Text] [Related]
3. Characterization of in vivo disulfide-reduction mediated drug release in mouse kidneys.
Yang JJ; Kularatne SA; Chen X; Low PS; Wang E
Mol Pharm; 2012 Feb; 9(2):310-7. PubMed ID: 22171616
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of EC140: a novel folate-targeted vinca alkaloid conjugate.
Leamon CP; Reddy JA; Vlahov IR; Kleindl PJ; Vetzel M; Westrick E
Bioconjug Chem; 2006; 17(5):1226-32. PubMed ID: 16984132
[TBL] [Abstract][Full Text] [Related]
5. Folate receptor-specific antitumor activity of EC131, a folate-maytansinoid conjugate.
Reddy JA; Westrick E; Santhapuram HK; Howard SJ; Miller ML; Vetzel M; Vlahov I; Chari RV; Goldmacher VS; Leamon CP
Cancer Res; 2007 Jul; 67(13):6376-82. PubMed ID: 17616697
[TBL] [Abstract][Full Text] [Related]
6. Regioselective synthesis of folate receptor-targeted agents derived from epothilone analogs and folic acid.
Vlahov IR; Vite GD; Kleindl PJ; Wang Y; Santhapuram HK; You F; Howard SJ; Kim SH; Lee FF; Leamon CP
Bioorg Med Chem Lett; 2010 Aug; 20(15):4578-81. PubMed ID: 20594844
[TBL] [Abstract][Full Text] [Related]
7. Preclinical antitumor activity of a novel folate-targeted dual drug conjugate.
Leamon CP; Reddy JA; Vlahov IR; Westrick E; Dawson A; Dorton R; Vetzel M; Santhapuram HK; Wang Y
Mol Pharm; 2007; 4(5):659-67. PubMed ID: 17874843
[TBL] [Abstract][Full Text] [Related]
8. Comparative preclinical activity of the folate-targeted Vinca alkaloid conjugates EC140 and EC145.
Leamon CP; Reddy JA; Vlahov IR; Westrick E; Parker N; Nicoson JS; Vetzel M
Int J Cancer; 2007 Oct; 121(7):1585-92. PubMed ID: 17551919
[TBL] [Abstract][Full Text] [Related]
9. Comparative evaluation of the biological properties of reducible and acid-sensitive folate prodrugs of a highly potent doxorubicin derivative.
Abu Ajaj K; El-Abadla N; Welker P; Azab S; Zeisig R; Fichtner I; Kratz F
Eur J Cancer; 2012 Sep; 48(13):2054-65. PubMed ID: 21937219
[TBL] [Abstract][Full Text] [Related]
10. EC-145, a folate-targeted Vinca alkaloid conjugate for the potential treatment of folate receptor-expressing cancers.
Dosio F; Milla P; Cattel L
Curr Opin Investig Drugs; 2010 Dec; 11(12):1424-33. PubMed ID: 21154124
[TBL] [Abstract][Full Text] [Related]
11. Folic acid modified cationic γ-cyclodextrin-oligoethylenimine star polymer with bioreducible disulfide linker for efficient targeted gene delivery.
Zhao F; Yin H; Zhang Z; Li J
Biomacromolecules; 2013 Feb; 14(2):476-84. PubMed ID: 23323627
[TBL] [Abstract][Full Text] [Related]
12. Folate receptor specific anti-tumor activity of folate-mitomycin conjugates.
Reddy JA; Westrick E; Vlahov I; Howard SJ; Santhapuram HK; Leamon CP
Cancer Chemother Pharmacol; 2006 Aug; 58(2):229-36. PubMed ID: 16331500
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and activity of a folate targeted monodisperse PEG camptothecin conjugate.
Henne WA; Kularatne SA; Hakenjos J; Carron JD; Henne KL
Bioorg Med Chem Lett; 2013 Nov; 23(21):5810-3. PubMed ID: 24064501
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo evaluation of (99m)Tc-DO3A-EA-Folate for receptor-mediated targeting of folate positive tumors.
Mishra G; Hazari PP; Kumar N; Mishra AK
J Drug Target; 2011 Nov; 19(9):761-9. PubMed ID: 21425922
[TBL] [Abstract][Full Text] [Related]
15. Imaging the folate receptor on cancer cells with 99mTc-etarfolatide: properties, clinical use, and future potential of folate receptor imaging.
Maurer AH; Elsinga P; Fanti S; Nguyen B; Oyen WJ; Weber WA
J Nucl Med; 2014 May; 55(5):701-4. PubMed ID: 24732155
[TBL] [Abstract][Full Text] [Related]
16. Targeting folate receptors to treat invasive urinary bladder cancer.
Dhawan D; Ramos-Vara JA; Naughton JF; Cheng L; Low PS; Rothenbuhler R; Leamon CP; Parker N; Klein PJ; Vlahov IR; Reddy JA; Koch M; Murphy L; Fourez LM; Stewart JC; Knapp DW
Cancer Res; 2013 Jan; 73(2):875-84. PubMed ID: 23204225
[TBL] [Abstract][Full Text] [Related]
17. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
[TBL] [Abstract][Full Text] [Related]
18. Folate-functionalized nanoparticles for controlled ergosta-4,6,8(14),22-tetraen-3-one delivery.
Liang X; Sun Y; Liu L; Ma X; Hu X; Fan J; Zhao Y
Int J Pharm; 2013 Jan; 441(1-2):1-8. PubMed ID: 23262423
[TBL] [Abstract][Full Text] [Related]
19. Folate-vinca alkaloid conjugates for cancer therapy: a structure-activity relationship.
Leamon CP; Vlahov IR; Reddy JA; Vetzel M; Santhapuram HK; You F; Bloomfield A; Dorton R; Nelson M; Kleindl P; Vaughn JF; Westrick E
Bioconjug Chem; 2014 Mar; 25(3):560-8. PubMed ID: 24564229
[TBL] [Abstract][Full Text] [Related]
20. Enhancing the therapeutic range of a targeted small-molecule tubulysin conjugate for folate receptor-based cancer therapy.
Leamon CP; Reddy JA; Vlahov IR; Dorton R; Bloomfield A; Vetzel M; Klein PJ; Westrick E; Xu LC; Wang Y
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1151-1160. PubMed ID: 28451831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
